A deal to acquire Alkermes spinout Mural Oncology is Xoma’s fourth since June and the latest evidence of interest in buying ...

The agreement values Mural Oncology at up to $36.2 million, with shareholders set to receive a base cash payment and ...

Xoma Royalty is ravenous for biotechs, and the Bay Area licensing aggregator has found its next meal in Mural Oncology. | ...

Purchased mezagitamab royalty and milestone rights held by BioInvent International and will secure royalty economic interests in two early-stage partnered assets through XOMA Royalty’s recently ...

Mural Oncology has agreed to be acquired by biotechnology royalty aggregator XOMA Royalty in a deal worth up to $38.8 million. Mural on Wednesday said XOMA will pay an initial $2.035 a share in cash, ...

Clinical-stage California-based biotech Mural Oncology and XOMA Royalty Corporation , a biotechnology royalty aggregator have entered into a definitive agreement pursuant to which XRA 5 Corp., a newly ...

Mural Oncology plc (NASDAQ: MURA), a clinical-stage immuno-oncology company, and XOMA Royalty Corporation (NASDAQ: XOMA), a biotechnology royalty aggregator, announced today they have entered into a ...

Detailed price information for Xoma Corp 8.625% (XOMAP-Q) from The Globe and Mail including charting and trades.

XOMA Royalty Corporation (XOMA) on Wednesday reported second-quarter net income of $9.2 million. On a per-share basis, the ...

Turnstone Stockholders Received $0.34 Per Share in Cash Plus Contingent Value Right - EMERYVILLE, Calif., Aug. 11, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA) ("XOMA Royalty" or ...

Purchased mezagitamab royalty and milestone rights held by BioInvent International and will secure royalty economic interests in two early-stage partnered assets through XOMA Royalty’s recently announ ...

Key Points Revenue (GAAP) beat estimates by 39.5% in Q2 2025, rising to $13.1 million on substantial milestone receipts. Recurring royalty income remained modest, with only $2.6 million from ...